EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

L. Y. Dirix, F. Tonnesen, J. Cassidy, R. Epelbaum, W. W. Ten Bokkel Huinink, N. Pavlidis, R. Sorio, T. Gamucci, I. Wolff, A. Te Velde, J. Lan, J. Verweij

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

Original languageEnglish
Pages (from-to)2019-2022
Number of pages4
JournalEuropean Journal of Cancer
Volume32
Issue number11
DOIs
Publication statusPublished - Oct 1996

Fingerprint

apaziquone
Colorectal Neoplasms
Stomach
Breast Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Drug Therapy
Alkylating Agents
Proteinuria
Pharmaceutical Preparations
Colonic Neoplasms
Nausea
Vomiting
Appointments and Schedules
Pancreatic Carcinoma
Clinical Studies

Keywords

  • Breast cancer
  • Colorectal cancer
  • EO9
  • Gastric cancer
  • Pancreatic cancer
  • Phase II study
  • Proteinuria
  • Renal toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Dirix, L. Y., Tonnesen, F., Cassidy, J., Epelbaum, R., Ten Bokkel Huinink, W. W., Pavlidis, N., ... Verweij, J. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. European Journal of Cancer, 32(11), 2019-2022. https://doi.org/10.1016/0959-8049(96)00226-2

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. / Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Ten Bokkel Huinink, W. W.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; Te Velde, A.; Lan, J.; Verweij, J.

In: European Journal of Cancer, Vol. 32, No. 11, 10.1996, p. 2019-2022.

Research output: Contribution to journalArticle

Dirix, LY, Tonnesen, F, Cassidy, J, Epelbaum, R, Ten Bokkel Huinink, WW, Pavlidis, N, Sorio, R, Gamucci, T, Wolff, I, Te Velde, A, Lan, J & Verweij, J 1996, 'EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group', European Journal of Cancer, vol. 32, no. 11, pp. 2019-2022. https://doi.org/10.1016/0959-8049(96)00226-2
Dirix, L. Y. ; Tonnesen, F. ; Cassidy, J. ; Epelbaum, R. ; Ten Bokkel Huinink, W. W. ; Pavlidis, N. ; Sorio, R. ; Gamucci, T. ; Wolff, I. ; Te Velde, A. ; Lan, J. ; Verweij, J. / EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. In: European Journal of Cancer. 1996 ; Vol. 32, No. 11. pp. 2019-2022.
@article{ad935df1f12b43199a7dba4c0fe206c3,
title = "EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group",
abstract = "In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3{\%} of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45{\%} of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.",
keywords = "Breast cancer, Colorectal cancer, EO9, Gastric cancer, Pancreatic cancer, Phase II study, Proteinuria, Renal toxicity",
author = "Dirix, {L. Y.} and F. Tonnesen and J. Cassidy and R. Epelbaum and {Ten Bokkel Huinink}, {W. W.} and N. Pavlidis and R. Sorio and T. Gamucci and I. Wolff and {Te Velde}, A. and J. Lan and J. Verweij",
year = "1996",
month = "10",
doi = "10.1016/0959-8049(96)00226-2",
language = "English",
volume = "32",
pages = "2019--2022",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

AU - Dirix, L. Y.

AU - Tonnesen, F.

AU - Cassidy, J.

AU - Epelbaum, R.

AU - Ten Bokkel Huinink, W. W.

AU - Pavlidis, N.

AU - Sorio, R.

AU - Gamucci, T.

AU - Wolff, I.

AU - Te Velde, A.

AU - Lan, J.

AU - Verweij, J.

PY - 1996/10

Y1 - 1996/10

N2 - In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

AB - In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

KW - Breast cancer

KW - Colorectal cancer

KW - EO9

KW - Gastric cancer

KW - Pancreatic cancer

KW - Phase II study

KW - Proteinuria

KW - Renal toxicity

UR - http://www.scopus.com/inward/record.url?scp=0030271681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030271681&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(96)00226-2

DO - 10.1016/0959-8049(96)00226-2

M3 - Article

VL - 32

SP - 2019

EP - 2022

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -